Showing posts with label First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer. Show all posts
Showing posts with label First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer. Show all posts
Monday, December 4, 2017

FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer

›
Genentech, a member of the Roche Group  announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Appl...